Combination Regimens May Expand Options for HR+ Breast Cancer Post-CDK4/6 Inhibitors
Patients with hormone receptor (HR)–positive breast cancer who have experienced disease progression on a frontline CDK4/6 inhibitor in the metastatic setting may benefit from continuing CDK4/6 inhibition or switching to a different class of agents …